The hepatitis C virus (HCV) NS3 protein possesses both protease and helicase activities and is essential for virus replication and maturation. Specific inhibition of NS3 enzymatic activity can be achieved by antibody binding. Transduction of hepatocytes with encoding cDNA leading to intracellular expression of antibody fragments is expected to terminate HCV replication in infected cells. The objective of the present study was the generation of human antibody fragments that neutralize the viral NS3 helicase activity for gene therapeutic applications and drug design. A human immunoglobulin phage-display library cloned from bone marrow aspirate of patients infected with HCV was used for affinity selection against HCV NS3 helicase. Antibody fragments with high affinity to HCV helicase were isolated. To evaluate the inhibitory potential of isolated single-chain antibody fragments, a helicase-mediated, DNA-unwinding enzymatic assay was developed in ELISA format. Recombinant protein comprising the full-length HCV NS3 helicase domain was expressed in the baculovirus expression system. Recombinant antibodies that inhibit the HCV helicase at nanomolar concentrations, with efficacies ranging from 20 % to complete abrogation of enzymatic unwinding activity, were identified. These antibody fragments may be useful for novel gene therapeutic strategies that employ intracellular immunization and may provide new insights into the design of small molecule inhibitors of essential HCV proteins.
AlvarezR. D.,
BarnesM. N.,
Gomez-NavarroJ.8 other authors2000; A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6:3081–3087
BoelE.,
VerlaanS.,
PoppelierM. J.,
WesterdaalN. A.,
Van StrijpJ. A.,
LogtenbergT.2000; Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239:153–166
BouHamdanM.,
DuanL. X.,
PomerantzR. J.,
StrayerD. S.1999; Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther 6:660–666
ChenS. Y.,
KhouriY.,
BagleyJ.,
MarascoW. A.1994b; Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A 91:5932–5936
ChoH. S.,
HaN. C.,
KangL. W.,
ChungK. M.,
BackS. H.,
JangS. K.,
OhB. H.1998; Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem 273:15045–15052
GalunE.,
ErenR.,
SafadiR.11 other authors2002; Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 35:673–679
GrakouiA.,
WychowskiC.,
LinC.,
FeinstoneS. M.,
RiceC. M.1993; Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67:1385–1395
GramH.,
MarconiL. A.,
BarbasC.III,
ColletT. A.,
LernerR. A.,
KangA. S.1992; In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A 89:3576–3580
HijikataM.,
MizushimaH.,
TanjiY.,
KomodaY.,
HirowatariY.,
AkagiT.,
KatoN.,
KimuraK.,
ShimotohnoK.1993; Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci U S A 90:10773–10777
HoogenboomH. R.,
WinterG.1992; By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro
. J Mol Biol 227:381–388
HsuC. C.,
HwangL. H.,
HuangY. W.,
ChiW. K.,
ChuY. D.,
ChenD. S.1998; An ELISA for RNA helicase activity: application as an assay of the NS3 helicase of hepatitis C virus. Biochem Biophys Res Commun 253:594–599
JeanD.,
TellezC.,
HuangS.,
DavisD. W.,
BrunsC. J.,
McConkeyD. J.,
HinrichsS. H.,
Bar-EliM.2000; Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19:2721–2730
KabatE. A.,
WuT. T.,
PerryH. M.,
GottesmanK. S.,
FoellerC.1991Sequences of Proteins of Immunological Interest , 5th edn. Bethesda, MD: National Technical Information;
KimJ. L.,
MorgensternK. A.,
GriffithJ. P.,
DwyerM. D.,
ThomsonJ. A.,
MurckoM. A.,
LinC.,
CaronP. R.1998; Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89–100
KitamuraY.,
IshikawaT.,
OkuiN.,
KobayashiN.,
KandaT.,
ShimadaT.,
MiyakeK.,
YoshiikeK.1999; Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. J Acquir Immune Defic Syndr Hum Retrovirol 20:105–114
KolykhalovA. A.,
AgapovE. V.,
RiceC. M.1994; Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 68:7525–7533
LohmannV.,
KornerF.,
KochJ.,
HerianU.,
TheilmannL.,
BartenschlagerR.1999; Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110–113
MarascoW. A.,
LaVecchioJ.,
WinklerA.1999; Human anti-HIV-1 Tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 231:223–238
MarksJ. D.,
HoogenboomH. R.,
BonnertT. P.,
McCaffertyJ.,
GriffithsA. D.,
WinterG.1991; By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581–597
MhashilkarA. M.,
LaVecchioJ.,
EberhardtB.9 other authors1999; Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther 10:1453–1467
PangP. S.,
JankowskyE.,
PlanetP. J.,
PyleA. M.2002; The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J 21:1168–1176
PflugheberJ.,
FredericksenB.,
SumpterR.Jr,
WangC.,
WareF.,
SodoraD. L.,
GaleM.Jr2002; Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A 99:4650–4655
PopeA. R.,
EmbletonM. J.,
MernaughR.1996; Construction and use of antibody gene repertoires. In Antibody Engineering: a Practical Approach pp 1–40 Edited by
McCaffertyJ.,
HoogenboomH.,
ChiswellD.
Oxford: IRL Press;
PoznanskyM. C.,
FoxallR.,
MhashilkarA.,
CokerR.,
JonesS.,
RamstedtU.,
MarascoW.1998; Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther 9:487–496
PreugschatF.,
AverettD. R.,
ClarkeB. E.,
PorterD. J.1996; A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J Biol Chem 271:24449–24457
RichardsonJ. H.,
HofmannW.,
SodroskiJ. G.,
MarascoW. A.1998; Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther 5:635–644
RoutledgeE. G.,
GormanS. D.,
ClarkM.1993; Reshaping antibodies for therapy. In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man Edited by
ClarkM.
Cambridge: Cambridge University Press;
SchoutenA.,
RoosienJ.,
BakkerJ.,
SchotsA.2002; Formation of disulfide bridges by a single-chain Fv antibody in the reducing ectopic environment of the plant cytosol. J Biol Chem 277:19339–19345
SuzichJ. A.,
TamuraJ. K.,
Palmer-HillF.,
WarrenerP.,
GrakouiA.,
RiceC. M.,
FeinstoneS. M.,
CollettM. S.1993; Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol 67:6152–6158
TessmannK.,
ErhardtA.,
HaussingerD.,
HeintgesT.2002; Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase. J Virol Methods 103:75–88
TomeiL.,
FaillaC.,
SantoliniE.,
De FrancescoR.,
La MonicaN.1993; NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67:4017–4026
WardellA. D.,
ErringtonW.,
CiaramellaG.,
MersonJ.,
McGarveyM. J.1999; Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. J Gen Virol 80:701–709
WuJ.,
NantzM. H.,
ZernM. A.2002; Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 7:D717–D725
YangS. H.,
LeeC. G.,
SongM. K.,
SungY. C.2000; Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease. Virology 268:132–140